Dr. Tomalty has been active as a clinical chemist for more than 40 years and she is well known among the clinical chemistry community for her many contributions to our profession. She is a member of the CSCC, the BC Association of Laboratory Physicians Chemistry and Science Section, and the AACC.

Dr. Tomalty was accepted into the Post-doctoral Clinical Chemistry Training Program at the University of Toronto, graduating with a Diploma in 1981 and received her certification in Clinical Biochemistry from the Canadian Society of Clinical Chemists (CSCC) in 1982. In 1984, the Canadian Academy of Clinical Biochemistry (CACB) came into being and she became a Founding Fellow of the CACB.

Dr. Tomalty was hired as the first Clinical Biochemist at the North York General Hospital and then joined Douglass Medical Laboratory (now owned by Dynacare) in Ottawa as a Clinical Chemist. Later she appointed as Technical Director of Chemistry and Hematology. Dr. Tomalty then became the Laboratory Coordinator of the Montreal General Hospital responsible for administration of all the clinical laboratories, and then went on to lead the laboratory integration team of the three hospitals of the McGill University Health Centre. Dr. Tomalty’s career then took her back to Ottawa as a Clinical Chemist with Abbott Point of Care, manufacturer of the i-STAT System. Her final position began in 2007 when she joined LifeLabs Burnaby Reference Laboratory in BC as a Clinical Biochemist. She retired on March 4, 2022, after over 40 years of service to the Clinical Biochemistry Laboratory profession.

Cheryl was primarily focused on service in her many different roles and capacities in the clinical laboratories where she worked. However, Dr. Tomalty also contributed her time to professional organizations, provincial committees, and teaching. She was a member of the CSCC Maintenance of Competency program, the precursor to the CACB PD program. Cheryl was an Executive Council Member of the Ontario Society of Clinical Chemists (OSCC) from 2001-2003, Vice-President from 2003-2005, and President of the from 2005-2007. She became a member of the CACB Board in 2011-2014 overseeing the applications for Fellowship and then Chair of the CACB from 2015-2017. From 2008 to 2014, she was one of the Associate Editors of the CSCC News. Cheryl was invited to become a member of the Chemistry and Point of Care Testing Advisory Committee of the BC Diagnostic Accreditation Program (DAP), the agency that oversees the clinical laboratory regulations and accreditation on behalf of the College of Physicians and Surgeons of BC. From 2012-2014, she and other provincial colleagues revamped the accreditation standards for the chemistry and POCT devices in terms of QC requirements, maintenance of competency, critical result reporting, and troubleshooting.

Cheryl holds an appointment as Clinical Assistant Professor in the Dept. of Pathology and Laboratory Medicine at UBC where she has taught several topics in clinical biochemistry. Dr. Tomalty was involved with introduction of the Fecal Immunochemical Test (FIT) in BC as part of the implementation of the BC Cancer Colon Screening Program and was a member of the BC Clinical and Support Services FIT Working Group and the FIT Technical Advisory Group. In the latter group she collaborated with Medical and Laboratory technical experts in enhancing and providing oversight of the provincial FIT Quality Assurance Program. During Dr. Tomalty’s career she has worked and contributed in the academic environment, hospital laboratory, commercial laboratory, and industry settings.

1. The Award shall be presented as a mark of recognition of outstanding achievement in and/or contribution to the field of clinical chemistry.
2. The Award shall usually be presented annually, but if in the opinion of the Awards Committee no suitable candidate is available in any year, the Award shall not be made.
3. Siemens has agreed to make an annual contribution of $3,000 CDN to sponsor this award. A framed certificate and an honorarium in the amount of $1,500 shall accompany the Award. The balance of $1,500 remaining after the honorarium shall be used to meet the administrative expenses, the production of the framed scroll, and to make a contribution towards expenses involved in ensuring the attendance of the recipient at the Annual Conference of the Society.
4. The Awards Committee shall choose the recipient of the Award.
5. The Awards Committee shall report its choice to the Council of the Society at its Winter Meeting in the year for which the Award is made.
6. The President of the Society will notify the recipient(s) of the award and inform Siemens Inc. of the name of the recipient(s) of the Award not later than March 1, in the year for which the Award is made.   7. The recipient of the Award is not usually expected to give an address or give a paper, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.  A representative of Siemens shall be invited to participate in the presentation.
7. No formal nomination procedure is specified, but members of the Society may propose suitable candidates to the Awards Committee through the Head Office of the Society.  Curriculum vitae and other suitable documentation in support of the nominee must accompany nominations from the membership.  Proposals shall be solicited annually in the Newsletter of the Society.
8. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the sponsor of the Award.  Council of the Society and the corporate sponsor of this award should review these terms of reference a minimum of once every 5 years.

Toronto’s Drug Checking Pilot Program at St. Michael’s Hospital and the Centre for Addiction and Mental Health (CAMH)

In response to the opioid crisis, Toronto Drug Checking team designed and developed a Drug Checking Service in 2017 as an integrated harm reduction tool and public health monitoring strategy. This involves clinical laboratory testing of pills, powders, liquids or used paraphernalia to identify the composition of unknown street drug substances. This testing was implemented in the clinical biochemistry laboratories at St Michael’s Hospital and the Centre for Addiction and Mental Health (CAMH) in Toronto thanks to a generous 5-year grant from Health Canada.

For people who use drugs (PWUD), drug checking allows for informed decision-making and the option to avoid ingestion/injection of previously unknown drugs with potentially dangerous adulterants (e.g., carfentanil). As part of a harm reduction strategy, it also connects individuals with other supports and services like safe housing, counselling, and medical attention. From a public health point of view, it allows for monitoring and surveillance of the unregulated street drug supply that can inform paramedics, clinicians, and hospitals; helping to better respond to the overdose crisis. It also provides data to policy makers at the provincial and national level, enabling a better understanding and better response to a crisis that is constantly changing. In 2018, the initial pilot program was the first of its kind in North America and was successfully funded by Health Canada at $2.14 million CAD for 5 years, and by St Michael’s Hospital foundation for $150,000 CAD. The service model (Maghsoudi et al. 2020) involves collaboration with Toronto Public Health, St Michael’s Hospital, CAMH, and Toronto’s Safe Consumption Sites (SCS), and allows people who use drugs (PWUDs) to anonymously submit 1-10 mg of their drug (1/10th a single use dose) for drug analysis by mass spectrometry at St Michael’s Hospital or CAMH. The Drug Checking Service has been incredibly successful thus far and has allowed us to characterize the extremely toxic and highly unpredictable street drug supply in Canada (Scarfone et al. 2022), demonstrated by unexpected contaminants such as xylazine (Bowles et al. 2021), synthetic cannabinoids (Ti et al. 2021), and designer benzodiazepines (Scarfone et al. 2022). The emergence of synthetic opioids – including fentanyl and fentanyl analogs – has been a major factor in the rise of mortality rates, and are being further characterized by our drug checking service in terms of prevalence and quantity in the street drug supply. This data is directly submitted to Health Canada on a monthly basis to provide the essential data they lack, in an effort to help inform policy makers and potential funding programs (i.e. Health Canada Substance Use and Addictions Program-SUAP). More recently (in February 2021), our Drug Checking Program has begun to identify the emergence of a new potent opioid drug class in Canada’s street drug supply, nitazene opioids (i.e. isotonitazene, etonitazene), that are 5-10x more potent than fentanyl. The findings were presented in collaboration with Public Health Ontario (video link: https://www.youtube.com/watch?v=cBOlS4Ahk-A), as well as internationally (American Association of Clinical Chemists (AACC) 2021 scientific meeting).

This program has inspired other provinces (more recently Alberta and Saskatchewan) to consider Drug Checking as a harm reduction tool and have reached out to our team for information and assistance.

Toronto’s Drug Checking program is lead by a group of scientists, clinical biochemists, and managers based at St Michael’s Hospital and the Centre for Addiction and Mental Health (CAMH). The core members include:

Dr. Dan Werb (Epidemiologist, St Michael’s Hospital)
Dr. Daniel Beriault (Head of Biochemistry, St Michael’s Hospital)
Dr. Sarah Delaney (Clinical Biochemist, St Michael’s Hospital)
Dr. Cristiana Stefan (Clinical Biochemist, CAMH)
Mark Evert (Research technician, St Michael’s Hospital)
Ernest Wong (Mass Spectrometry specialist, CAMH)
Karen MacDonald (Research Program Manager, St Michael’s Hospital)
Hayley Thompson (Senior Research Coordinator, St Michael’s Hospital)

The program also involves
–      Dr. Margaret Thompson (ED physician, director of the Ontario Poison Control Center)
–      Five Safe Consumption Sites (with many members at each site)
–      Toronto Public Health
–      Many members of the community (as part of the Drug Checking Advisory Committee)

1. The Award shall be presented to a Clinical Laboratory in Canada that has distinguished itself by outstanding accomplishment through innovation in the field of Clinical Chemistry, or Pathology and Laboratory Medicine for projects where a CSCC member was directly involved. This award is intended to encourage and recognize excellence in Clinical Laboratory Services especially in the role of improving the quality of health care, improving patient outcomes, and promoting a positive public image to clinical laboratories and laboratory professionals.
2. Eligible organizations for this award include:
   1. Private, Academic and Government Clinical Laboratories and Laboratory divisions.
   2. Rural and Regional Clinical Laboratories and Clinical Laboratory Departments.
3. Laboratories demonstrating outstanding accomplishments in one or more of the following areas completed within the last two calendar years are eligible for consideration:
   1. Innovation in strategic planning and implementation of laboratory services based on best practices.
   2. Innovation in development of new laboratory programs (e.g. new tests, facilities, and changes in practice).
   3. Innovation in teaching and education. 3.4. Promotion of a positive public image for laboratory medicine.
4. Nominations for this award will be received from members of the CSCC to the Awards Committee through the Head Office of the Society. Nominations for this award will include:
   1. A summary of the accomplishment(s) of the nominated organization with supporting documentation.
   2. A letter of support from a CSCC member involved in the project for which the organization is being nominated.
   3. A letter of support from the nominee’s organization administrative team (Signed by a Department Director, VP, or CEO).
5. Nominees having received this award within the last 3 years will not be eligible to receive this award for a current year.
6. Nominations for this award shall be solicited annually in the Newsletter of the Society.
7. The Award shall usually be presented annually, but if in the opinion of the Awards Committee there is no suitable candidate(s) available in any year, the Award shall not be made.
8. The CSCC supporting member and a representative from the administration of hospital or institution represented in the project will be invited to accept the award (plaque and display item) at the CSCC Annual Meeting banquet. The award will be presented by a representative from Roche Diagnostics. The award will cover airfare, accommodations and expenses for 2 nights for both recipients, as per the CSCC Travel Guidelines. Photographs and a brief summary of the award will be provided to the hospital or institution for their publication.
9. The Awards Committee shall select one of the nominees for the Award for recommendation to Council of the Society.
10. The Awards Committee shall report its recommendation to the Council of the Society for approval at its Winter Council meeting in the year for which the Award is to be made.
11. The President of the Society will notify the recipient organization of the Award, and inform Roche Diagnostics of the name of the recipient of the award, not later than March 1 in the year in which the Award is made.
12. The recipient of the Award is not usually expected to give an address, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.
13. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the donor of the Award and should be reviewed at least every five years.

https://cscc-sccc.ca/wp-content/uploads/Awards/InnovationAward/Application_Form_CSCC_Laboratory_Innovation_Award.pdf

Edward Randell, PhD, FCACB, DCC

Dr. Randell has been active as a clinical biochemist and researcher for more than 35 years, with a consistent track record of advancing science and clinical practice through his personal involvement in research.

Dr. Edward W. Randell, PhD, FCACB, DCC, is a Certified Clinical Chemist, Fellow of the Canadian Academy of Clinical Biochemistry and Fellow of the American Association for Clinical Chemistry. He is currently Clinical Chief, Department of Laboratory Medicine, Eastern Health, St. John’s, NL and Director of Clinical Laboratory Services, Laboratory Reform Initiative, Medical Services-Health and Community Services, Government of Newfoundland Labrador.

Dr. Randall is a Professor and Vice-Chair, Discipline of Laboratory Medicine, Faculty of Medicine, Memorial University, St. John’s, NL. Dr. Randall also has cross appointments in the Discipline of Medicine, Faculty of Medicine, School of Pharmacy, and Department of Biochemistry, Faculty of Science, Memorial University.

Dr. Randall holds many distinctions and awards such as;
• Memorial University Medical Research Foundation Cox Award March 2022
• IFCC visiting Lecturer to the Asia-Pacific Federation for Clinical Biochemistry Nov 2019
• Canadian Society of Clinical Chemists award for Outstanding Contributions to Clinical Chemistry Aug 2017.
• Canadian Society of Clinical Chemists award for Education Excellence June 2016.
• Canadian Academy of Clinical Biochemistry award for Outstanding Service to the Profession of Clinical Biochemistry June 2016.

Dr. Randall has been very successful throughout his career at securing grant funding for his research, working collaboratively with other healthcare professionals, and mentoring young researchers (including clinical biochemists, research fellows, medical students, and medical laboratory technologists). At last count Ed has produced 132 peer-reviewed publications and over 90 abstracts and presentations. His most recent research has involved metabolomics, nutrition, epidemiology, and various aspects of clinical lab quality and his work has had 5332 citations.

Dr. Randell has been engaged with over 100 students and colleagues and most notably, he has also encouraged and enabled many others to be involved in laboratory medicine research and contribute in their own right. Dr. Randall can be seen working on the bench along side members of his research team, is easily accessible and enthusiastic as a mentor.

1. The Award shall be presented to an individual or group, as a mark of recognition of their contribution to research directly or indirectly related to clinical chemistry in Canada.
2. The Award shall usually be presented annually, but if in the opinion of the Awards Committee no group or individual is available in any year, the Award shall not be made.
3. Ortho-Clinical Diagnostics have agreed to make an annual contribution of $3,000 CDN. The Award shall be accompanied by a framed certificate and by an honorarium in the amount of $1,500. The balance of $1,500 remaining after the honorarium shall be used to meet the administrative expenses, the production of the framed scroll, and to make a contribution towards expenses involved in ensuring the attendance of the recipient at the Annual Conference of the Society.
4. The Awards Committee shall choose the recipient(s) of the Award.
5. The Awards Committee shall report its choice to the Council of the Society at its Winter Meeting for the year for which the Award is made.
6. The President of the Society will notify the recipient(s) of the award and inform Ortho Clinical Diagnostics of the name of the recipient(s) of the Award not later than March 1, in the year for which the Award is made. . 7. The recipient(s) of the Award is (are) not usually expected to give an address or present a paper, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.  A representative of Ortho-Clinical Diagnostics shall be invited to participate in the presentation.
7. No formal nomination procedure is specified, but members of the Society may propose suitable candidates to the Awards Committee through the Head Office of the Society.  Curriculum vitae and other suitable documentation in support of the nominee must accompany nominations from the membership.  Proposals shall be solicited annually in the Newsletter of the Society.
8. The amendment of these Terms of Reference is the responsibility of the Council of the Society, subject to the concurrence of the sponsor of the Award.  Council of the Society and the corporate sponsor of the Award should review these Terms of Reference a minimum of once every five years.

Peter Kavsak, PhD, FCACB, FAACC, FCCS

Dr. Kavsak is a Clinical Biochemist at Hamilton Regional Laboratory Medicine Program (HRLMP) and Professor in the Department of Pathology and Molecular Medicine, Division of Clinical Pathology, Faculty of Health Sciences, McMaster University. Dr. Kavsak is a Fellow of the Canadian Academy of Clinical Biochemistry (FCACB), a Fellow, National Academy of Clinical Biochemistry, a Fellow of the American Association for Clinical Chemistry Academy, and a Fellow of the Canadian Cardiovascular Society (FCCS).

In addition to performing his job as a Clinical Biochemist at an exemplary level, Dr. Kavsak demonstrates an extraordinary commitment to teaching and research as a Professor in the Department of Pathology and Molecular Medicine at McMaster University. Dr. Kavsak in involved in teaching with the graduate and postgraduate Clinical Chemistry training programs at both mainly McMaster University and University of Toronto.

During the last 16 years he has taught 18 Clinical Chemistry Fellows and 25 Medical Biochemistry residents which are now working in many provinces across Canada. Dr. Kavsak demonstrates his teaching commitment not only for his graduate students, the Clinical Chemistry Fellows and Medical Biochemistry residents, but also for the medical laboratory technicians and technologists. Dr. Kavsak has provided tremendous support and is always willing to teach and share what he knows. Residents and fellows love reaching out to him and enjoy working with him as he encourages them to think, read, question, discuss, and challenge specific topics. Dr. Kavsak’s door is always open for discussions with everyone including laboratory assistants, medical laboratory technologists, managers, fellows, and other colleagues.

Dr. Kavsak has over 200 publications in laboratory medicine, over 50 of which are published with one of his fellows or technologists. He has had over 100 invited local, national, and international presentations, has supervised MSc, PhD students as well as being a committee member and external examiner for both MSc and PhDs. He has taught in the MD program since 2007 being a tutor for 19 different medical foundations. Apart from intensive teaching and research, he is also an editor, editorial board member and reviewer for many laboratory and clinical journals. He was Editor-in-Chief, Clinical Biochemistry, from January 2012 to November 2017.

The education award is designed to acknowledge the value of exemplary skills, leadership, creativity, mentoring and other intangible aspects of the work needed to accomplish the teaching mission of the laboratory medicine field. Dr. Kavsak truly satisfies these criteria.

The Award shall be presented to an individual or group as a mark of recognition of outstanding contribution to education in the field of clinical chemistry.

2. The Award shall usually be presented annually, but if in the opinion of the Awards Committee no suitable candidate is available in any year, the Award shall not be made.
3. Beckman Coulter Canada Inc. have committed to an annual contribution of $3,000 CDN. A framed certificate and an honorarium in the amount of $1,500 shall accompany the Award.  The balance of $1,500 remaining after the honorarium shall be used to meet the administrative expenses, the production of the framed scroll and to make a contribution towards the expenses involved in ensuring the attendance of the recipient at the Annual Conference of the Society.
4. The Awards Committee shall choose the recipient(s) of the Award.
5. The Awards Committee shall report its choice to the Council of the Society at its Winter Meeting in the year for which the Award is made.
6. The President of the Society will notify the recipient(s) of the award and inform Beckman Coulter Canada Inc. of the name of the recipient(s) of the Award not later than March 1, in the year for which the Award is made.
7. The recipient(s) of the Award is (are) not usually expected to give an address or present a paper, but the Award and the reading of the citation shall usually be made at the Annual Conference of the Society.  Representatives of Beckman Coulter Canada Inc. shall be invited to participate in the presentation.
8. No formal nomination procedure is specified, but members of the Society may propose suitable candidates to the Awards Committee through the Head Office of the Society. Curriculum vitae and other suitable documentation in support of the nominee must accompany nominations from the membership. Proposals shall be solicited annually in the Newsletter of the Society.
9. The amendment of these Terms of Reference is the responsibility of the Council, subject to the concurrence of the sponsor of the Award.  The CSCC Council and the corporate sponsor of the Award should review these Terms of Reference a minimum of once every five years.

ELIGIBILITY REQUIREMENTS
1. Applicants must be members of the CSCC.
2. Applicants must be enrolled EITHER in a CACB-accredited clinical biochemistry training program OR
in a Royal College of Physicians and Surgeons of Canada-accredited medical biochemistry training
program.

ADDITIONAL REQUIREMENTS
1. The Host Laboratory must perform clinical service in biochemistry, hematology, microbiology,
immunology, genetics, and/or a related area.
2. The Host Laboratory must be located outside of the home city of the Applicant’s training program.
3. Funds must be used within one year of being awarded or before completion of the training program,
whichever is earlier.
4. Successful Applicants must submit a summary article of their visit to CSCC News before completion
of their training program. The article should describe goals that were achieved during the visit and
how Applicants plan to apply their new knowledge in the future. Applicants should coordinate the
length and timing of their articles with the Editor in Chief of the publication.

APPLICATION PROCESS
An application form is included with this Terms of Reference. Applicants are to send their completed
application form, together with all other required materials, to CSCC Head Office (office@cscc.ca).
Applications are accepted on an on-going basis throughout the year.

AWARDING OF GRANTS
CSCC Head Office will forward all applications to the Head of CSCC Education & Scientific Affairs Division
who will then appoint up to three (3) reviewers per application. All reviewers are required to be CSCC
members; one should be the Head of Professional Affairs and one should be a CSCC Councillor if there is
no conflict of interest. In awarding the grants, preference will be given to Applicants who will be in their
final year of study during the proposed visit and/or have not previously received a CSCC Trainee Elective
Visit Grant. Whenever possible, grants will be distributed across two or more training programs each
year. Head Office will notify Applicants of the reviewer panel’s decision within one (1) month of
receiving applications.

Updated and approved by CSCC Council on June 2, 2018.

Terms of Reference and Application Form

[Original: 2005]

[Revised 2006/06]

[Abbott Diagnostics sponsored from 2005 to 2019]

Download PDF

Terms of Reference
1. The Grant shall be presented to a member of the CSCC to support leadership and/or administrative
contributions in the field of Clinical Chemistry or Pathology and Laboratory Medicine. This award is
intended to encourage and support the administrative and leadership role of Laboratory Physicians
and Scientists including (but not limited to):
a) administrative positions in hospitals, universities, private laboratories, government and
industry,
b) participation in committees of Provincial, National and International professional and
regulatory agencies,
c) leadership role in the strategic planning and implementation of laboratory services.
2. The Grant shall usually be presented annually, but if in the opinion of the Awards Committee no
suitable candidate(s) is available in any year, the Grant shall not be made. The deadline for
application for the grant shall be November 30 of the previous year.
3. Recipients of the Grant shall receive a maximum of $1500 from a total of $3,000 donated by Abbott
Diagnostics and a framed certificate. The grant is to be distributed to as many applicants as is
appropriate. This honorarium is to be used to support and facilitate the administrative/leadership
activities of the recipient (eg travel expenses associated with participating on national/international
committees (eg IFCC, WHO, NIH, etc), presentations at conferences, educational courses in
administration and management.
4. The Awards Committee shall choose the recipient of the Award.
5. The Awards Committee shall report its choice to the Council of the Society not later than January
15th in the year for which the Grant is made.
6. The recipient of the Grant is not usually expected to give an address or present a paper, but the
Grant and the reading of the citation shall usually be made at the Annual Conference of the Society.
A representative of the Company shall be invited to participate in the presentation.
7. Candidates will submit an application to the Awards Committee through the Head Office of the
Society. Proposals shall be solicited annually in the Newsletter of the Society.
8. The amendment of these Terms of Reference is the responsibility of the Council, subject to the
concurrence of the donor of the Award and should be reviewed at least every five years.

CSCC Grant for Leadership Application Form

Download Trainee Grant TOR

Participation in the Annual Conference of the CSCC provides trainees in laboratory medicine with a valuable opportunity to increase their knowledge in laboratory medicine and related fields, to discuss their work with colleagues, and to establish novel collaborative relationships.

CSCC is providing a limited number of Trainee Travel Grants each year in support of this important facet of laboratory medicine training. Trainees are encouraged to apply for these grants if they meet all the following criteria:

1. They are members of the CSCC.
2. They are enrolled EITHER in a CACB-accredited clinical biochemistry training program OR in a Royal College of Physicians and Surgeons of Canada-accredited medical biochemistry training program.
3. They are presenting work at the Annual Conference of the CSCC that they performed during their current traineeship.

In awarding the travel grants, the CSCC Awards Committee will consider the following additional criteria:

1. Preference will be given to trainees:

• In their final year of study,
• That have not previously received a CSCC Trainee Travel Grant,
• Presenting more than one abstract at the conference, AND
• Who reside outside of the city where the conference is being held.

2. Abstracts will be evaluated based on the amount of work involved in the study and the applicability of the results to the practice of Clinical/Medical Biochemistry. Preference will be given to clinical abstracts, followed by analytical abstracts, followed by basic research.
3. Whenever possible, grants will be distributed across two or more training programs. Eligible trainees must notify CSCC Head Office (office@cscc.ca) of their intention to apply after submission of their abstract(s) through the abstract submission system; notification must occur within 2 weeks of the abstract submission deadline.

Trainees must send ALL the following information to CSCC Head Office to be considered for this Grant:

1. Name and institution of their training program,
2. Current year of training,
3. A copy of their submitted abstract, AND
4. Proof of acceptance of the abstract for presentation (Submitted within two weeks of notification of acceptance of abstract(s) by the conference organizing committee). Applicants will be notified by Head Office as soon as possible after all complete travel grant applications have been reviewed.

Updated and approved by CSCC Council on April 12, 2017.

CSCC Grant for Educational Activities

1. The Grant(s) shall be presented to a Full member(s) of the CSCC to support their educational activities and/or development of the profession in the field of Clinical Chemistry or Pathology and Laboratory Medicine. The grant is intended to encourage and support Full CSCC members who require additional funding, beyond that provided by their employer, to attend national/international conferences or take additional courses, including (but not limited to): a. Attendance at the CSCC annual meeting or another national or international meeting relevant to Laboratory Medicine b. Visiting other laboratories to obtain specialized expertise in areas of Laboratory Medicine c. Attendance at provincial, national, or international Courses, Workshops, Task Forces or Committees that promote professional development in Laboratory Medicine.
2. This grant is not intended to cover examination fees or related expenses
3. Candidates will submit an application to the Awards Committee through the Head Office of the Society. The deadline for applications is November 30th each year. Candidates will submit with their application a statement explaining why this award is required, and a proposed budget. If their employer provides funds for education and travel, the candidates shall explain why these funds cannot be used for the purpose requested.
4. The grant shall usually be presented annually, but, if in the opinion of the Awards Committee, no suitable candidate is available, the Grant shall not be made. A maximum of three awards shall be given in any fiscal year.
5. Recipients of the Grant shall receive a maximum of $3000, sponsored by the CSCC Council.  Awarding of this grant is subject to available funds from the CSCC.  Grant amounts may be reduced, or the grant may not be funded in any given year, at the discretion of the Council.
6. The Awards Committee shall choose the recipient(s) of the grant.
7. The Awards Committee shall report its choice(s) to the Council at the Winter Council meeting in the year for which the grant is made.
8. The President of the Society will notify recipient(s) not later than March 1 in the year in which the grant is made.
9. Grant recipients must provide a full accounting of expenses not more than sixty days following completion of the funded activity.
10. The recipient(s) is not usually required to give an address or paper, but the grants will be announced and the awardee(s) recognized at the Annual Meeting of the Society.
11. The amendment of the Terms of Reference is the responsibility of the Council., The terms of reference should be reviewed every five years.

CSCC Grant for Education Application Form

CSCC REGIONAL GRANT TOR

1. PROVINCIAL EDUCATION GRANTS Purpose

The purpose of Provincial Education Grants is to assist provincial societies with the provision of educational activities for their members. To further this goal, funding is allocated in advance to each provincial section so that they can plan events with the assurance that funds will be available. Funds will only be disbursed following the actual event. Amount of Grant: up to a maximum of $1,000 payable upon receipt of invoices

2. TRAVELLING LECTURESHIP

Purpose

Host cities are responsible for any hospitality extended to the Travelling Lecturer. Generally this consists of a dinner on one of the nights the lecturer is in town. The host city is also responsible for an additional honorarium for the lecturer, if he/she is asked to give additional talks after the initial one. CSCC covers all other costs including travel, accommodation, and honorarium.

Amount of Grant: up to a maximum of $1,000 payable upon receipt of invoices

PROCEDURE

1. Application for the grant is to be made to CSCC Head Office and the Head of the Education and Scientific Affairs Division (ESAD) with supporting documentation of the event in the form of copies of the program and a proposed budget.
2. Request for reimbursement must be received at CSCC Head Office by November 30 of the year in which the event occurred.
3. If a host does not have the ability to fund an event, application for an advance may be made to the Head ESAD. At the discretion of the Head and the Treasurer, funds can be advanced on the understanding that documentation of how the funds were used will be provided after the event takes place.

Approved June 2015

CSCC REGIONAL GRANT APPLICATION FORM